Basilea Pharmaceutica AG (BSLN) — Cash Flow Quality Index
Basilea Pharmaceutica AG (BSLN) has a Cash Flow Quality Index of 1.60x as of December 2025. Operating cash flow of CHF39.03 Million exceeds net income of CHF24.44 Million, indicating high earnings quality where cash backs reported profits. Explore Basilea Pharmaceutica AG (BSLN) cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Basilea Pharmaceutica AG Cash Flow Quality Index (2010–2025)
Historical Cash Flow Quality Index for Basilea Pharmaceutica AG across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Basilea Pharmaceutica AG cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Basilea Pharmaceutica AG (2010–2025)
Year-by-year earnings quality comparison for Basilea Pharmaceutica AG. For live market cap and the full company financial profile, see Basilea Pharmaceutica AG market capitalisation.
| Year | Quality Index | Operating CF (CHF) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.54x | CHF62.09 Million | CHF40.24 Million | ▲ +61.0% |
| 2024 | 0.96x | CHF74.36 Million | CHF77.59 Million | ▼ -29.7% |
| 2023 | 1.36x | CHF14.24 Million | CHF10.45 Million | ▲ +134.6% |
| 2022 | 0.58x | CHF7.06 Million | CHF12.15 Million | ▼ -41.4% |
| 2010 | 0.99x | CHF106.64 Million | CHF107.56 Million | — |